ST. LOUIS, MO--(Marketwire - January 21, 2011) - Mobius Therapeutics™, LLC, a St. Louis-based ophthalmic company, has received Orphan Drug Designation from the Food and Drug Administration for their platform product, Mitosol™, for use in "Prevention of recurrence of pterygium after its surgical excision."
By granting orphan drug status to Mitosol™ for this indication, Mobius Therapeutics™ will expand its reach to general ophthalmologists and ocular surface specialists, as these surgeons routinely perform pterygium removal procedures.
"The designation of Mitosol™ as an orphan drug will help Mobius Therapeutics™ provide surgeons and allied health personnel with improved convenience, safety and precision in their treatment of pterygium," said Ed Timm, President of Mobius Therapeutics™.
Orphan Drug Designation is granted specifically to treat rare medical diseases or conditions. "Removal of pterygium is a specialized indication for the use of Mitosol™ in ophthalmology, precisely the type of application to be protected by orphan drug status," said Timm.
Pterygium is a triangular patch of tissue that obstructs vision by growing over the inner side of the eye and is usually caused by degeneration of the cornea due to prolonged exposure to sun or wind. The use of Mitosol™ following the removal of pterygium helps stop the recurrence of similar obstructions.
"The final approval of Mitosol™ will greatly improve the treatment of pterygium," said Timm. "It will help provide patients with quality assurance, surgeons with precision and convenience, and our investors with unprecedented value."
About Mobius Therapeutics, LLC:
Mobius Therapeutics is an early stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. It is awaiting regulatory approval, with additional product applications in earlier stages of development.